Study Enrollment

Your details will not be published or shared.

Clinical Trial

S1605; Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The purpose of this study is to test the good and bad effects of the investigational drug atezolizumab in stopping non-muscle invasive bladder cancer from coming back and progressing to muscle invasive bladder cancer. Atezolizumab is not approved by the FDA for treatment of this type of cancer.

Eligibility Criteria

  • - Recurrent bladder cancer - 18 years of age or older

Contact Information

    Sharad Ghamande, MD

    (706) 721-3992